| Literature DB >> 31963194 |
Dorota Kostrzewa-Nowak1, Anna Nowakowska1, Teresa Zwierko1, Maciej Rybak2, Robert Nowak1.
Abstract
The study was aimed at designing a health exercise program appealing to inactive young men, and then testing the men's metabolic responses to the program using common diagnostic markers of general health. Six men, aged 22-29 years, took a part in training program to increase their motor performance and improve general health conditions. Body composition parameters, clinical chemistry variables (metabolites, albumin, total protein, ferritin, C reactive protein, lipid profile, ions, and selected enzymes activities) and blood morphology parameters were determined. Motor performance measured before and after a 4-month-long macrocycle indicated an increase in endurance, pace, and agility of the participants. Significant differences were found in analyzed enzymes activities. There was a significant increase in C-reactive protein levels from pre- to post-training. Additionally, changes in hematological biomarkers were seen that suggest erythropoiesis might significantly increase, specifically during the last 2-month-long mesocycles. The proposed training program induced small improvements in endurance, pace, and agility. It was also confirmed that changes in aspartate (AST) and alanine (ALT) activities emerge before any increase in creatine kinase (CK) activity that is important in monitoring of the training loads. Observed changes in red blood cell-related parameters suggest increase in erythropoiesis in the second half of the training cycle.Entities:
Keywords: blood; health exercise program; motor performance; physical activity
Mesh:
Substances:
Year: 2020 PMID: 31963194 PMCID: PMC7014064 DOI: 10.3390/ijerph17020578
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Macrocycle training protocol. OB 7 × 2—seven exercises × two circuits; TPS 50 × 4—length of football track (m) × number of repetitions, 60 × 4—length of “parachute run” (m) × number of lengths covered; INT 30 (8 × 2)—interval including 30 m of sprint (number of 330 m—long laps × 2 min per lap); PP 8 × 22—number of inroads × number of ascents; BCO 5/4—distance of run (km) × load (kg), below there is a time for completion of the BCO exercise.
Motor performance outcomes at baseline and post-training.
| Variable | Participant No. | Baseline | Post-Training | PC Ratio |
|---|---|---|---|---|
| Time of outdoor run on 1 km distance (min) | 1 | 3.57 | 3.32 | 0.93 |
| 2 | 4.12 | 3.58 | 0.87 | |
| 3 | 4.32 | 3.51 | 0.81 | |
| 4 | 3.15 | 2.51 | 0.79 | |
| 5 | 3.38 | 3.05 | 0.90 | |
| 6 | 3.52 | 3.02 | 0.86 | |
| VO2 max (mL/kg/min) | 1 | 43.06 | 48.86 | 1.13 |
| 2 | 40.18 | 42.86 | 1.07 | |
| 3 | 36.86 | 44.33 | 1.20 | |
| 4 | 53.74 | 62.47 | 1.16 | |
| 5 | 47.34 | 57.07 | 1.20 | |
| 6 | 44.11 | 58.15 | 1.32 | |
| Pace (s) | 1 | 4.23 | 4.06 | 0.96 |
| 2 | 3.67 | 3.63 | 0.99 | |
| 3 | 4.21 | 4.01 | 0.95 | |
| 4 | 3.76 | 3.68 | 0.98 | |
| 5 | 4.02 | 3.89 | 0.97 | |
| 6 | 4.24 | 4.13 | 0.97 | |
| Agility (s) | 1 | 17.86 | 16.82 | 0.94 |
| 2 | 15.77 | 15.32 | 0.97 | |
| 3 | 16.68 | 15.47 | 0.93 | |
| 4 | 14.84 | 14.23 | 0.96 | |
| 5 | 14.85 | 14.52 | 0.98 | |
| 6 | 15.44 | 14.79 | 0.96 |
PC ratio—personal change ratio (post-training divided by baseline values).
Participants’ body composition variables during the training macrocycle.
| Variable | t0 | t1 | t2 | t3 | t4 |
|
|---|---|---|---|---|---|---|
| Weight (kg) | 82.5 | 84.6 | 85.4 | 87.1 | 91.6 | NS |
| (75.6–98.5) | (77.0–96.6) | (75.3–98.1) | (79.2–97.5) | (81.9–96.3) | ||
| BMI (kg/m2) | 25.6 | 25.5 | 25.0 | 26.9 | 27.8 | NS |
| (23.0–28.8) | (23.4–28.9) | (23.2–28.7) | (24.4–28.5) | (25.3–28.4) | ||
| BMR (kJ) | 9150 | 9238 | 9199 | 8908 | 9253 | NS |
| (8602–10,309) | (8506–9560) | (8468–10,125) | (8782–878) | (9247–9782) | ||
| Fat (%) | 14.9 | 16.4 | 12.7 | 17.6 | 17.0 | NS |
| (7.0–21.5) | (8.7–22.7) | (7.1–18.5) | (9.8–18.5) | (15.9–20.9) | ||
| Fat mass (kg) | 12.2 | 13.6 | 11.1 | 15.3 | 15.8 | NS |
| (5.3–20.1) | (7.4–21.7) | (6.0–16.7) | (7.8–18.0) | (14.1–19.7) | ||
| FFM (kg) | 73.5 | 74 | 74.4 | 71.8 | 74.6 | NS |
| (69.8–102.0) | (69.1–77.2) | (69.1–81.4) | (71.4–79.5) | (74.5–78.8) | ||
| TBW (kg) | 53.8 | 54.2 | 54.5 | 52.6 | 54.6 | NS |
| (51.1–60.7) | (50.6–56.5) | (50.6–59.6) | (52.3–58.2) | (54.5–57.7) |
BMR—basal metabolic range; BMI—body mass index; Fat—the percentage of fat; FFM—fat-free mass; TBW—total body water. Data presented as medians (minimum−maximum) values. NS—not significant.
Activities of participants’ selected plasma enzymes during the training macrocycle.
| Variable | t0 | t1 | t2 | t3 | t4 |
|
|
|---|---|---|---|---|---|---|---|
| Amylase | 53.2 | 62.8 | 56.8 | 96.1 | 63.8 | NS | - |
| (35.7–108.9) | (35.8–104.4) | (39.7–112.4) | (35.0–116.2) | (32.4–106.0) | |||
| AST | 42.1 | 29.1 | 30.5 | 31.2 | 53.9 | 0.0242 | 0.0590 (t4 vs. t1) |
| (36.1–58.9) | (25.5–37.4) | (25.7–53.8) | (26.1–67.5) | (34.0–73.3) | |||
| ALT | 16.9 | 23.2 | 20.8 | 36.5 | 31.1 | 0.0156 | 0.0263 (t3 vs. t0) |
| (14.7–26.8) | (15.7–25.6) | (17.7–75.4) | (22.3–75.3) | (25.7–35.4) | |||
| CK | 275 | 131 | 191 | 124 | 280 | NS | - |
| (109–485) | (87.8–196.7) | (172–562) | (114–845) | (145–732) | |||
| GGT | 16.0 | 20.2 | 17.1 | 16.5 | 18.2 | NS | - |
| (12.0–24.9) | (14.1–36.1) | (13.2–27.8) | (13.3–27.2) | (16.6–31.9) | |||
| LDH | 280 | 314 | 356 | 290 | 383 | 0.0285 | 0.0399 (t4 vs. t0) |
| (212–338) | (257–424) | (340–465) | (272–420) | (358–520) | |||
| ALP | 112.3 | 88.2 | 81.6 | 61.2 | 78.0 | 0.0486 | 0.0348 (t3 vs. t0) |
| (73.7–135.0) | (51.9–104.3) | (61.5–98.9) | (61–96.2) | (58.3–83) |
Data presented as median (minimum−maximum) values. AST—aspartate aminotransferase; ALT—alanine aminotransferase; CK—creatine kinase; GGT—γ-glutamyltransferase; LDH—lactate dehydrogenase; ALP—alkaline phosphatase. Significance levels of differences observed between analyzed time points (t0 vs. t1 vs. t2 vs. t3 vs. t4) were assessed using Friedman’s analysis of variance followed by post-hoc Dunn’s test with Bonferroni correction. NS—not significant.
The values of biomarkers in participants’ blood during the training macrocycle.
| Variable | t0 | t1 | t2 | t3 | t4 |
|
|
|---|---|---|---|---|---|---|---|
| Cr | 101.1 | 110.0 | 111.0 | 110.0 | 105.5 | NS | - |
| (96.0–116.0) | (92.0–123.0) | (91.0–124.0) | (99.0–136.0) | (91.0–128.0) | |||
| U | 8.4 | 6.7 | 7.3 | 7.2 | 6.4 | NS | - |
| (6.5–12.1) | (5.1–7.1) | (4.9–9.5) | (3.7–8.3) | (5.3–6.7) | |||
| UA | 291 | 270 | 329 | 293 | 297 | NS | - |
| (191–402) | (247–386) | (214–406) | (249–306) | (269–351) | |||
| DBIL | 6.02 | 5.54 | 5.43 | 5.37 | 6.85 | NS | - |
| (4.49–7.31) | (2.37–6.87) | (3.65–9.78) | (2.17–8.29) | (1.36–10.75) | |||
| TBIL | 6.74 | 12.42 | 11.82 | 11.23 | 12.10 | NS | - |
| (4.05–9.98) | (7.87–14.2) | (8.42–15.25) | (8.10–13.36) | (4.98–16.82) | |||
| total protein | 67.6 | 67.3 | 67.0 | 63.2 | 65.8 | NS | - |
| (63.4–76.2) | (64.6–74.8) | (63.7–71.0) | (61.1–69.1) | (60.3–70.1) | |||
| albumin | 49.6 | 48.2 | 47.4 | 46.7 | 46.3 | NS | - |
| (44,4–50.7) | (45.2–50.6) | (46.9–49.2) | (43.7–47.5) | (44.5–49.2) | |||
| CRP | 0.0 | 0.6 | 2.3 | 8.05 | 8.13 | 0.005 | 0.0387 (t3 vs. t0) |
| (0.0) | (0.0–1.6) | (0.0–3.3) | (0.84–18.9) | (1.77–14.12) | |||
| TC | 3.82 | 4.39 | 4.09 | 4.50 | 4.01 | NS | - |
| (3.27–4.45) | (3.54–4.86) | (3.46–4.74) | (3.29–4.64) | (3.55–4.74) | |||
| LDL-C | 2.02 | 2.24 | 2.01 | 2.40 | 2.13 | NS | - |
| (1.11–2.60) | (1.14–2.61) | (1.43–2.61) | (1.12–2.55) | (1.05–2.44) | |||
| HDL-C | 1.40 | 1.80 | 1.66 | 1.84 | 1.75 | NS | - |
| (1.15–1.84) | (1.33–2.13) | (1.45–1.76) | (1.19–1.92) | (1.42–2.22) | |||
| TG | 0.83 | 0.93 | 0.97 | 0.59 | 0.90 | NS | - |
| (0.50–1.53) | (0.43–1.77) | (0.50–1.51) | (0.54–2.00) | (0.60–1.04) | |||
| ferritin | 144.5 | 143.2 | 141.7 | 144.7 | 143.0 | NS | - |
| (140.9–146.2) | (141.6–147.1) | (139.9–146.3) | (143.4–147.7) | (140–147) | |||
| Fe | 19.7 | 21.1 | 19.7 | 18.9 | 15.6 | NS | - |
| (12.7–31.1) | (18.8–28.2) | (17.9–24.2) | (18.5–20.8) | (11.6–31.5) | |||
| Mg | 0.85 | 0.8 | 0.79 | 0.86 | 0.84 | NS | - |
| (0.81–0.91) | (0.74–0.89) | (0.78–0.82) | (0.83–0.87) | (0.78–0.87) | |||
| P (mmol/L) | 1.53 | 1.36 | 1.21 | 1.19 | 1.26 | NS | - |
| (1.36–1.55) | (0.81–1.64) | (1.05–1.41) | (0.00–1.42) | (0.87–1.52) | |||
| Ca | 2.58 | 2.53 | 2.56 | 2.40 | NS | - | |
| (2.52–2.74) | (2.44–2.54) | (2.42–2.62) | (2.37–2.48) |
Data presented as median (minimum−maximum) values. Cr—creatinine; U—urea; UA—uric acid; DBIL—direct bilirubin; TBIL—total bilirubin; CRP—C-reactive protein; TC—total cholesterol; LDL-C—low-density lipoprotein cholesterol; HDL-C—high-density-lipoprotein cholesterol; TG—triglycerides; Fe—iron; Mg—magnesium; Ca—calcium; P—phosphorus. Significance levels of differences observed between analyzed time points (t0 vs. t1 vs. t2 vs. t3 vs. t4) were assessed using Friedman’s analysis of variance followed by post-hoc Dunn’s test with Bonferroni correction. NS—not significant.
Participants’ blood morphology during the training macrocycle.
| Variable | t0 | t1 | t2 | t3 | t4 |
|
|
|---|---|---|---|---|---|---|---|
| RBC | 4.92 | 4.87 | 5.08 | 4.84 | 5.12 | NS | - |
| (4.13–5.07) | (4.36–5.22) | (4.98–5.17) | (4.57–5.17) | (4.48–5.93) | |||
| HGB | 8.60 | 8.40 | 8.45 | 8.60 | 8.85 | NS | - |
| (7.40–9.40) | (7.60–9.00) | (8.40–8.50) | (7.7–9.1) | (7.50–10.3) | |||
| HTC | 0.46 | 0.46 | 0.47 | 0.47 | 0.49 | NS | - |
| (0.39–048) | (0.41–0.49) | (0.46–0.48) | (0.41–0.49) | (0.42–0.57) | |||
| MCV | 95 | 95 | 93 | 95 | 96 | NS | - |
| (92–95) | (92–96) | (90–96) | (91–97) | (93–97) | |||
| MCH | 1.80 | 1.75 | 1.66 | 1.76 | 1.72 | 0.0176 | 0.013 (t2 vs. t0) |
| (1.74–1.85) | (1.68–1.76) | (1.62–1.70) | (1.68–1.78) | (1.67–1.77) | |||
| MCHC | 19.1 | 18.4 | 17.9 | 18.5 | 18.0 | 0.0018 | 0.0098 (t2 vs. t0) |
| (18.7–19.4) | (13.3–18.5) | (17.8–18.1) | (18.3–18.6) | (17.9–18.3) | |||
| RDW | 10.8 | 11.4 | 11.4 | 11.3 | 11.6 | 0.0332 | 0.0178 (t4 vs. t0) |
| (10.6–11.3) | (11.0–11.9) | (10.9–1.9) | (11.3–11.6) | (11.4–12.0) | |||
| WBC | 8.1 | 7.1 | 6.8 | 7.4 | 6.1 | NS | - |
| (6.0–10.2) | (6.3–9.6) | (6.1–7.4) | (5.1–7.8) | (4.2–6.8) | |||
| LYM | 39.0 | 38.4 | 45.0 | 42.9 | 38.8 | NS | - |
| (27.0–49.0) | (19.6–47.1) | (42.1–47.9) | (39.0–45.4) | (18.7–41.5) | |||
| MON | 3.8 | 4.5 | 4.4 | 4.5 | 4.4 | NS | - |
| (3.1–5.5) | (4.2–5.4) | (4.0–4.8) | (4.2–4.6) | (2.7–5.9) | |||
| GRA | 56.9 | 56.7 | 50.6 | 52.5 | 56.8 | NS | - |
| (47.3–70.4) | (48.4–76.2) | (48.1–53.1) | (50.4–56.5) | (52.6–78.6) | |||
| LYM | 2.90 | 3.10 | 3.00 | 3.00 | 2.05 | NS | - |
| (2.10–4.00) | (1.30–3.60) | (2.9–3.1) | (2.3–3.1) | (1.00–2.70) | |||
| MON | 0.20 | 0.30 | 0.25 | 0.30 | 0.20 | NS | - |
| (0.20–0.50) | (0.20–0.40) | (0.20–0.30) | (0.20–0.30) | (0.10–0.30) | |||
| GRA | 5.30 | 3.80 | 3.50 | 4.00 | 3.8 | NS | - |
| (3.50–5.80) | (3.30–5.60) | (3.00–4.00) | (2.6–4.5) | (2.4–4.6) | |||
| PLT | 236 | 259 | 290 | 254 | 234 | NS | - |
| (127–326) | (133–280) | (282–297) | (236–306) | (181–250) | |||
| MPV | 6.9 | 7.1 | 7.6 | 7.5 | 7.1 | NS | - |
| (6.8–9.5) | (6.5–9.6) | (7.3–7.8) | (6.8–8.1) | (6.5–7.5) | |||
| PCT | 0.18 | 0.18 | 0.22 | 0.19 | 0.17 | 0.0426 | 0.049 (t4 vs. t2) |
| (0.12–0.22) | (0.13–0.21) | (0.21–0.23) | (0.17–0.23) | (0.12–0.18) | |||
| PDW | 14.7 | 14.9 | 16.1 | 16.1 | 14.7 | NS | - |
| (14.6–17.9) | (14.0–20.1) | (15.8–16.3) | (15.8–16.5) | (14.2–15.9) |
Data presented as median (minimum−maximum) values. RBC—red blood cells count; HGB—hemoglobin; HTC—hematocrit; MCV—mean corpuscular volume; MCH—mean corpuscular hemoglobin; MCHC—mean corpuscular hemoglobin concentration; RDW—red blood cell distribution width; WBC—white blood cells count; LYM—lymphocytes; MON—monocytes; GRA—granulocytes; PLT—platelets count; MPV—mean platelet volume; PCT—plateletcrit; PDW—platelet distribution width. Significance levels of differences observed between analyzed time points (t0 vs. t1 vs. t2 vs. t3 vs. t4) were assessed using Friedman’s analysis of variance followed by post-hoc Dunn’s test with Bonferroni correction. NS—not significant.